Package Leaflet:Informationfor thepatient
Desvenlafaxine Neuraxpharm 50 mg prolonged-release tablets EFG
Read all of this leaflet carefully before you start takingthismedicine, because it contains important information for you.
Contents of the pack
Desvenlafaxine Neuraxpharm contains the active substance desvenlafaxine (as benzoate).
This medicine is an antidepressant that belongs to a group of medicines called serotonin and noradrenaline reuptake inhibitors (SNRIs). This group of medicines is used to treat depression.
It is not fully understood how antidepressants work, but they may help to increase the levels of serotonin and noradrenaline in the brain.
Desvenlafaxine is a treatment for adults.
Do not take Desvenlafaxine Neuraxpharm:
Warnings and precautions
Tell your doctor if you have had any of the following conditions before taking Desvenlafaxine or if they appear during treatment with this medicine:
Some medicines of the same group as Desvenlafaxine (called SSRIs/SNRIs) may cause sexual dysfunction symptoms (see section 4). In some cases, these symptoms persist after stopping treatment.
Desvenlafaxine may cause a feeling of restlessness or inability to sit or stand still during the first few weeks of treatment. You should inform your doctor if this happens.
Suicidal thoughts and worsening of your depression
If you are depressed, you may sometimes have thoughts of harming or killing yourself. These thoughts may increase when you first start taking antidepressants, as these medicines take time to work, usually around two weeks, but sometimes longer.
You may be more likely to think this way:
If you have thoughts of self-harm or suicide at any time, contact your doctor or go to a hospital directly.
You may find it helpful to tell a relative or close friendthat you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.
Medicines like desvenlafaxine (called SNRIs/SSRIs) may cause sexual dysfunction symptoms (see section 4). In some cases, these symptoms persist after stopping treatment.
Dry mouth
Dry mouth has been reported in 18% of patients treated with desvenlafaxine. This may increase the risk of tooth decay. Therefore, you should be careful with your oral hygiene.
Elderly patients
In some elderly patients, it cannot be ruled out that they may be more sensitive to desvenlafaxine.
Children and adolescents
This medicine should not normally be used in children and adolescents under 18 years of age.
Additionally, you should know that in patients under 18 years of age, there is an increased risk of side effects such as suicidal attempts, suicidal thoughts and hostility (mainly aggression, confrontational behaviour and anger) when taking this type of medicine.
Despite this, your doctor may prescribe this medicine to patients under 18 years of age when they decide it is the most convenient for the patient.
If your doctor has prescribed this medicine to a patient under 18 years of age and you want to discuss this decision, please go back to your doctor. You should inform your doctor if any of the above symptoms develop or worsen when these patients under 18 years of age are taking this medicine. Additionally, the long-term effects on safety and those related to growth, maturity and cognitive and behavioural development of this medicine have not yet been demonstrated.
Other medicines and Desvenlafaxine Neuraxpharm
Tell your doctor or pharmacist that you are taking, have recently taken or might take any other medicines.
It is especially important that you inform your doctor if you are taking any of the following medicines:
Serotonin syndrome or reactions similar to Neuroleptic Malignant Syndrome (NMS)
Rarely, a disorder called serotonin syndrome or reactions similar to NMS may occur, which can cause significant changes in brain, muscle and digestive system function due to high levels of serotonin in the body. This potentially life-threatening condition may occur when taking medicines like desvenlafaxine, particularly when taken with other medicines mentioned above.
See the section “Warnings and precautions” for possible side effects related to serotonin syndrome or reactions similar to NMS.
Switching antidepressants
When switching treatment from one antidepressant to desvenlafaxine, symptoms of withdrawal from the initial antidepressant have appeared. Your doctor may gradually reduce the dose of your initial antidepressant medication to help decrease these symptoms.
Interactions with laboratory tests
False positives for certain substances such as phencyclidine (PCP) and amphetamines may occur in urine analysis of patients who are taking or have taken desvenlafaxine, even several days after stopping treatment.
Using Desvenlafaxine Neuraxpharm with food, drinks and alcohol
The tablets of this medicine can be taken with or without food.
You should avoid drinking alcohol while taking this medicine.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Your doctor or midwife should know that you are taking this medicine. When similar medicines (SSRIs) are taken during pregnancy, there is an increased risk of a serious condition for the baby called persistent pulmonary hypertension of the newborn (PPHN), causing the baby to breathe faster and turn blue. These symptoms usually start during the first 24 hours after the baby is born. If your baby has these symptoms, you should contact your doctor and/or midwife immediately.
If you take Desvenlafaxine Neuraxpharm during pregnancy, inform your doctor and/or midwife, as your baby may experience withdrawal symptoms when born. These symptoms can appear soon after birth and may require hospitalization. The symptoms include difficulty feeding or breathing problems. If your baby has these or other symptoms when born and you are concerned, contact your doctor and/or midwife.
If you take Desvenlafaxine Neuraxpharm in the late stage of pregnancy, there may be an increased risk of heavy vaginal bleeding shortly after delivery, especially if you have a history of bleeding disorders.
Your doctor and/or midwife should know that you are taking desvenlafaxine to be able to advise you.
Desvenlafaxine passes into breast milk. There is a risk of an effect on the baby. Therefore, do not use this medicine during breastfeeding unless your doctor specifically tells you to.
Driving and using machines
This medicine may cause dizziness, drowsiness and blurred vision. Do not drive or use tools or machines until you know how this medicine affects you.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor again.
The recommended dose is 50 mg once a day. Your doctor may increase your dose to 100 mg once a day or even up to a maximum of 200 mg once a day if necessary.
If you have kidney problems or a history of kidney problems, consult your doctor as you may need to take a different dose of this medicine.
Desvenlafaxine Neuraxpharm should be taken orally, approximately at the same time each day. The tablets should be swallowed whole with liquid, without dividing, crushing, chewing or dissolving them.
If you take more Desvenlafaxine Neuraxpharmthan you should
Contact your doctor or pharmacist immediately if you take more of this medicine than your doctor has prescribed.
In case of overdose or accidental ingestion, consult your doctor or call the Toxicology Information Service, Tel. 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Desvenlafaxine Neuraxpharm
If you miss a dose, take it as soon as you remember. However, if it is already time for your next dose, skip the missed dose and take only one dose, as usual. Do not take a double dose to make up for the missed dose.
If you stop taking Desvenlafaxine Neuraxpharm
Do not stop taking Desvenlafaxine, or change the dose, without talking to your doctor first, even if you feel better.
If your doctor thinks you no longer need to take desvenlafaxine, they may ask you to reduce the dose slowly before stopping treatment completely.
It is known that patients experience side effects when they stop taking this medicine, especially if they have taken a high dose and for a long period of time or when treatment is stopped abruptly or the dose is reduced too quickly.
These side effects are: mood changes, irritability, agitation, dizziness, anxiety, confusion, headache, sleep disturbances, mania, tinnitus (ringing in the ears), seizures, nausea, fatigue, restlessness, diarrhoea, sweating and insomnia.
Although these symptoms are usually self-limiting, serious withdrawal symptoms have been reported. Therefore, the dose should be reduced gradually, whenever possible, under medical supervision, if you and your doctor decide to stop treatment with Desvenlafaxine. If you experience any of these or other troublesome symptoms, consult your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Desvenlafaxina can cause adverse effects, although not all people suffer from them.
Severe Adverse Effects
If you notice any of the following signs, inform your doctor immediately or go to the nearest hospital:
List of Possible Adverse Effects
The adverse effects and frequency (probability of occurrence) mentioned below have been observed in patients. In general, these adverse effects occurred more frequently during the first week of treatment.
Very Common Adverse Effects: affect more than 1 in 10 patients
Common Adverse Effects: affect up to 1 in 10 patients
Uncommon Adverse Effects: affect up to 1 in 100 patients
Rare Adverse Effects: affect up to 1 in 1000 patients
Frequency Not Known: cannot be estimated from available data.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after "CAD". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Desvenlafaxina Neuraxpharm
The active ingredient is desvenlafaxina (as benzoate).
Each tablet contains 50 mg of desvenlafaxina (as benzoate).
The other components are: hypromellose type 2208, 100 Pa.s (E464), microcrystalline cellulose (E460), talc (E553b), stearic acid (E570), magnesium stearate (E470b), colloidal anhydrous silica (E551).
The coating film of the 50 mg tablets consists of: Poly (vinyl alcohol) (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), yellow iron oxide (E172), and red iron oxide (E172).
Appearance of the Product and Package Contents
Light pink, round, biconvex tablet with a diameter of 9.6 ± 0.2 mm.
Packaged in Aluminum_PVC/PE/PVdC or Aluminum_OPA/Alu/PVC blisters.
Desvenlafaxina Neuraxpharm 50 mg is available in packages of 10, 20, 28, 30, 50, and 100 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Neuraxpharm Spain, S.L.U.
Avda. Barcelona, 69
08970 Sant Joan Despí
Barcelona - Spain
Manufacturer
PharOS MT Ltd.
HF62X, Hal Far Industrial Estate,
Birzebbugia BBG3000
Malta
This medicine is authorized in EEA member states under the following names:
Germany: Desveneurax 50 mg Retardtabletten
Portugal: Faxilex
Spain: Desvenlafaxina Neuraxpharm 50 mg prolonged-release tablets EFG
Italy: Faxilex
Austria: Desveneurax 50 mg Retardtabletten
Date of the Last Revision of this Prospectus:December 2021
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
The average price of DESVENLAFAXINE NEURAXPHARM 50 mg PROLONGED-RELEASE TABLETS in October, 2025 is around 10.19 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.